481 related articles for article (PubMed ID: 35163730)
1. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Blitz SE; Kappel AD; Gessler FA; Klinger NV; Arnaout O; Lu Y; Peruzzi PP; Smith TR; Chiocca EA; Friedman GK; Bernstock JD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163730
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.
Delwar ZM; Kuo Y; Wen YH; Rennie PS; Jia W
Cancer Res; 2018 Feb; 78(3):718-730. PubMed ID: 29118089
[TBL] [Abstract][Full Text] [Related]
3. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell plasticity in glioblastoma multiforme: a perspective on future directions in oncolytic virotherapy.
Kim DS
Future Oncol; 2020 Oct; 16(28):2251-2264. PubMed ID: 32744059
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions.
Liu J; Piranlioglu R; Ye F; Shu K; Lei T; Nakashima H
Front Cell Infect Microbiol; 2023; 13():1141034. PubMed ID: 37234776
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.
Shimizu K; Kahramanian A; Jabbar MADA; Turna Demir F; Gokyer D; Uthamacumaran A; Rajan A; Saad MA; Gorham J; Wakimoto H; Martuza RL; Rabkin SD; Hasan T; Wakimoto H
Cancer Lett; 2023 Sep; 572():216363. PubMed ID: 37619813
[TBL] [Abstract][Full Text] [Related]
10. Cutting both ways: the innate immune response to oncolytic virotherapy.
Mealiea D; McCart JA
Cancer Gene Ther; 2022 Jun; 29(6):629-646. PubMed ID: 34453122
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic viral therapy for gliomas: Advances in the mechanisms and approaches to delivery.
Romanishin A; Vasilev A; Khasanshin E; Evtekhov A; Pusynin E; Rubina K; Kakotkin V; Agapov M; Semina E
Virology; 2024 May; 593():110033. PubMed ID: 38442508
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
13. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
14. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
Tan DQ; Zhang L; Ohba K; Ye M; Ichiyama K; Yamamoto N
Eur J Immunol; 2016 Apr; 46(4):919-28. PubMed ID: 26763072
[TBL] [Abstract][Full Text] [Related]
15. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
Shoaf ML; Desjardins A
Neurotherapeutics; 2022 Oct; 19(6):1818-1831. PubMed ID: 35674873
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Zika Virus: New Option for Glioblastoma Treatment.
Zhou C; Chen Q; Chen Y; Qin CF
DNA Cell Biol; 2023 Jun; 42(6):267-273. PubMed ID: 36350682
[TBL] [Abstract][Full Text] [Related]
19. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
